Source comparison
Comparison Table: BPC-157 vs LL-37 in Chronic Infection Research
BPC-157 Angiogenesis via VEGF upregulation, nitric oxide modulation, tissue repair acceleration Indirect antimicrobial through immune restoration 200–500 mcg/day Subcutaneous injection, topical gel Moderate. Strong preclinical data, limited clinical Best for i
This comparison does not assign a generated winner or score.
- BPC-157
- Angiogenesis via VEGF upregulation, nitric oxide modulation, tissue repair acceleration
- Indirect antimicrobial through immune restoration
- 200–500 mcg/day
- Subcutaneous injection, topical gel
- Moderate. Strong preclinical data, limited clinical
- Best for infections complicated by impaired wound healing or vascular compromise
- LL-37
- Direct membrane disruption, biofilm degradation, immune chemotaxis via FPRL1
- Gram-positive/negative bacteria, fungi, some viruses
- 5–20 mg/day
- Subcutaneous injection, topical gel, intranasal
- Strong. Extensive in vitro and animal model data
- Best for biofilm-associated infections resistant to antibiotics
- Combined Protocol
- Synergistic restoration of immune function + direct pathogen targeting
- Broad-spectrum, particularly MRSA, Pseudomonas, diabetic ulcer pathogens
- BPC-157 400 mcg + LL-37 10 mg daily
- Subcutaneous or topical
- Emerging. 2023–2025 data shows superiority to monotherapy
- First-line consideration for chronic infections with both microbial and healing dysfunction